[18F]FDG PET/MRI in Endometrial Cancer: Prospective Evaluation of Preoperative Staging, Molecular Characterization and Prognostic Assessment
Cancers · 16.01.2026 · 18 (2) · 280
DOI: 10.3390/cancers18020280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 16.01.2026. Verfasst von Carolina Bezzi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Early and accurate characterization of endometrial cancer (EC) is crucial for patient management, but current imaging modalities lack in diagnostic accuracy and ability to assess molecular profiles. The aim of this study is to evaluate hybrid [18F]FDG PET/MRI’s diagnostic accuracy in EC staging and role in predicting tumor aggressiveness, molecular characterization, and recurrence.
Methods
A prospective study (ClinicalTrials.gov, ID:NCT04212910) evaluating EC patients undergoing [18F]FDG PET/MRI before surgery (2018–2024). Histology, immunohistochemistry, and patients’ follow-up (mean FU time: 3.13y) were used as the reference standard. [18F]FDG PET/MRI, PET only, and MRI only were independently reviewed to assess the diagnostic accuracy (ACC), sensitivity (SN), specificity (SP), and positive/negative predictive value (PPV, NPV). Imaging parameters were extracted from [18F]FDG PET and pcT1w, T2w, DWI, and DCE MRI. Spearman’s correlations, Fisher’s exact test, ROC-AUC analysis, Kaplan–Meier survival curves, log-rank tests and Cox proportional hazards models were applied.
Results
Eighty participants with primary EC (median age 63 ± 12 years) were enrolled, with 17% showing LN involvement. [18F]FDG PET/MRI provided ACC = 98.75%, SN = 98.75%, and PPV = 100% for primary tumor detection, and ACC = 92.41%, SN = 84.62%, SP = 93.94%, PPV = 73.33%, and NPV = 96.88% for LN detection. PET/MRI parameters predicted LN involvement (AUC = 79.49%), deep myometrial invasion (79.78%), lymphovascular space invasion (82.00%), p53abn (71.47%), MMRd (74.51%), relapse (82.00%), and postoperative administration of adjuvant therapy (79.64%). Patients with a tumor cranio-caudal diameter ≥ 43 mm and MTV ≥ 13.5 cm3 showed increased probabilities of recurrence (p < 0.001). Conclusions: [18F]FDG PET/MR showed exceptional accuracy in EC primary tumor and LN detection. Derived parameters demonstrated potential ability in defining features of aggressiveness, molecular alterations, and tumor recurrence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
- Radiology Department, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
- School of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy.
- Unit of Obstetrics and Gynaecology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
- Pathology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
- Department of Radiology, Massachusetts General Hospital. Harvard Medical School, Boston, MA 02114, USA.
ORCID-Profile: Carolina Bezzi, Tommaso Russo, Federico Fallanca, Ana Maria Samanes Gajate, Samuele Ghezzo, Miriam Sant'Angelo, Paola Scifo, Giorgia Mangili, Massimo Candiani, Francesco De Cobelli, Arturo Chiti, Maria Picchio
Zitieren
APA
Bezzi, C., Ironi, G., Russo, T., Candotti, G., Fallanca, F., Sabini, C., Samanes Gajate, A. M., Ghezzo, S., Bergamini, A., Sant'Angelo, M., Bocciolone, L., Brembilla, G., Scifo, P., Taccagni, G., Catalano, O. A., Mangili, G., Candiani, M., De Cobelli, F., Chiti, A., …, & Picchio, M. (2026). [18F]FDG PET/MRI in Endometrial Cancer: Prospective Evaluation of Preoperative Staging, Molecular Characterization and Prognostic Assessment. Cancers, 18(2), 280. https://doi.org/10.3390/cancers18020280
Vancouver
Bezzi C, Ironi G, Russo T, Candotti G, Fallanca F, Sabini C, et al. [18F]FDG PET/MRI in Endometrial Cancer: Prospective Evaluation of Preoperative Staging, Molecular Characterization and Prognostic Assessment. Cancers. 2026;18(2):280. doi:10.3390/cancers18020280
BibTeX
@article{Bezzi2026,
author = {Bezzi, Carolina and Ironi, Gabriele and Russo, Tommaso and Candotti, Giorgio and Fallanca, Federico and Sabini, Carlotta and Samanes Gajate, Ana Maria and Ghezzo, Samuele and Bergamini, Alice and Sant'Angelo, Miriam and Bocciolone, Luca and Brembilla, Giorgio and Scifo, Paola and Taccagni, GianLuca and Catalano, Onofrio Antonio and Mangili, Giorgia and Candiani, Massimo and De Cobelli, Francesco and Chiti, Arturo and Mapelli, Paola and Picchio, Maria},
title = {[18F]FDG PET/MRI in Endometrial Cancer: Prospective Evaluation of Preoperative Staging, Molecular Characterization and Prognostic Assessment},
journal = {Cancers},
year = {2026},
volume = {18},
number = {2},
pages = {280},
doi = {10.3390/cancers18020280}
}
EUVIMED